There are 67 marketed rare disease drugs in China that are included in the medical insurance, what i

The first is to strengthen the drug protection for patients with rare diseases. Most of the symptomatic drugs for rare diseases, as well as drugs for rare diseases such as hemophilia, idiopathic pulmonary fibrosis, and amyotrophic lateral sclerosis, have been included in the medical insurance list. In the adjustment of the national medical insurance catalog, the first drugs for major diseases such as rare diseases are mainly considered.

Drugs for rare diseases, such as primary carnitine deficiency and young Parkinson's disease, were newly added to the list. Drugs for rare diseases, such as pulmonary hypertension and Niemann disease type C, have been included in the catalogue through access negotiations, and ** have dropped significantly.

The second is to give priority to ensuring the use of drugs for orphans and the determination of the scope of diseases. Prioritize the issue of orphan drugs that can be associated with rare diseases, and ensure that patients with rare diseases with clear diagnosis and effective treatment are fully protected. Since there are more than 6,000 rare diseases in the world, it is impossible to include all of them in the insurance system in a short period of time.

Therefore, the degree of social acceptance and national affordability should be taken as an important basis, and they can be gradually incorporated according to priority. Mainly in social medical insurance and public financial funds; At the same time, social charitable donation funds can be used as an important supplement. Promote multi-party payment models.

In addition, the accessibility of medical insurance for rare diseases has been significantly improved. Although drug price reductions are inevitable, the strategic procurement logic of exchanging volume for price is also valid in the field of rare diseases. Judging from the changing trend of drug sales after previous national negotiations, entering the national medical insurance catalogue is a necessary admission ticket for rare disease drugs.

Outside the national medical insurance catalog, some regions are actively exploring the inclusion of innovative drugs for individual rare diseases in different forms of local supplementary insurance.

It is important to know that there has been no significant increase in drug spending on medical insurance** and insured patients. Under the premise of overall controllable safety, the ability and level of medical insurance drug protection have been improved. More importantly, it can further guide pharmaceutical companies to form a reasonable and healthy value trend, and ultimately promote the high-quality development of China's pharmaceutical industry from the perspective of strategic purchasing by supporting innovation and value purchase, and deepen the supply-side reform of the pharmaceutical industry.

67% of the drugs for rare diseases that have been marketed in China are included in the medical insurance. 67% of the marketed drugs for rare diseases in China are among them, which greatly reduces the drug burden of patients. The characteristic is that the policy is appropriately tilted towards special groups such as rare diseases and children.

Generally, it is about 80% reduction, which is a very good thing for those who suffer from rare diseases, which can enhance their benefits.

It should be that some drugs used for rare diseases will be partially reimbursed through medical insurance, so that residents do not have to bear such high medical costs. And hospitalization can also be reimbursed.

The help it brings to patients includes the ability to reduce the corresponding economic consumption, so that rare diseases can be reduced.

The patient's family is more harmonious, which can give rare disease patients a chance to be reborn, and will not give up the hope of life because of the sky-high drug cost of rare diseases, and more importantly, it can allow more rare disease patients to persist for a long time until they recover, so rare disease drugs are included in the medical insurance, which is really very important, because this will be more helpful to rare disease patients.

Up to now, nearly 2,860 kinds of drugs in China have entered the national medical insurance catalog.

Among them, 67% of rare diseases are marketed drugs.

Already in it, this will be of better help to most patients with rare diseases, and can reduce the burden of medication on patients with alleviating diseases, although we don't want to admit it, but in fact, this is the case, many patients with rare diseases give up, because rare disease drugs are too expensive, if ordinary families can't afford to use them at all, they can only give up, and inclusion in medical insurance is equivalent to giving these rare disease patients a chance to be reborn.

Rare disease drugs can be included in the medical insurance, which is equivalent to allowing the families of rare disease patients to relieve the economic pressure to a certain extent, so as to make the family more harmonious, so that the relevant people in the family have hope and hope for the future of the family to live together peacefully, so that rare disease patients can let go of too much psychological burden, and at the same time, it can also make the parents of rare diseases work outside the home will not be so hard, and more importantly, it can enable those relatively poor rare disease families to buy relevant drugs to their own children. Give your child hope back to life.

Therefore, it is really crucial for rare disease drugs to be included in medical insurance, which will have a lot of help for most patients, so that these patients can continue to make themselves go on, so that they can be cured one day, and let themselves have hope of life, so that those families who can no longer support it have the motivation to continue to support and will not give up because of this.

The inclusion of drugs for rare diseases in medical insurance means that more and more rare patients can reduce the cost of medical treatment, which is a good thing for the public.

67% of the drugs for rare diseases have been included in social insurance, which has great benefits for patients with rare diseases, and patients rarely consider the cost during treatment.

Although China's medical security system has made great progress after the reform and opening up, achieving a basic medical security system covering the entire population is only the first step, and it is still far from universal medical insurance in the true sense。There are still many problems in China's medical insurance system in terms of insurance system, system differences, and fee control mechanisms, which affect the fairness and efficiency of the system. In addition, the problems existing in China's medical service system also have an important impact on the effective operation of the medical insurance system.

At present, 2,860 expensive drugs on the market have entered the national medical insurance catalog, and about 76% of the drugs for rare diseases have also been included in the medical insurance, which has greatly reduced the economic burden of disease patients in the country. In the past decade, China has increased from 100 million people participating in national medical insurance to 100 million people. China has also become the first country in the world to have the largest number of insured people, but this does not mean that China's health insurance system has matured.

At present, China's medical insurance is divided into urban employee medical insurance and resident medical insurance, and there are huge differences and shortcomings between these two types of medical insurance. There are huge differences in the level of financing and welfare protection between different health insurance systems and between different regions under the same health insurance system, reflecting that the current health care system needs to be improved in terms of fairness.

The per capita financing level of basic medical insurance for urban workers is about 2,600 yuan, and the financing level of basic medical insurance for urban and rural residents is about 400 yuan, which is twice as much as the latter two. In terms of basic medical insurance for urban and rural residents, Shanghai, which has the highest level of financing, is more than four times the national average. Gaps in the level of financing inevitably lead to gaps in the level of security.

For example, the actual reimbursement ratio of hospitalization expenses of employee medical insurance is about 83%, while the actual reimbursement ratio of hospitalization expenses of resident medical insurance is only about 50%, and the gap is obvious. In fact, due to the concentration of high-quality medical resources in big cities and large hospitals, there is also a big gap between urban and rural residents and residents in various regions in the quality of medical services they enjoy.

China's medical insurance system still lacks a wider range of social insurance, because there are more than 1,200 rare diseases in China, and not all of them have yet been included in social insurance.

Just recently, the National Health Insurance Administration issued an announcement on the progress of the adjustment of the medical insurance catalogue in 2022, one of the major features of which is that the policy is appropriately tilted towards special populations such as rare diseases and children. Because a total of 344 drugs have passed the preliminary review in this adjustment, including 19 drugs for rare diseases, and these 19 drugs for rare diseases have been included in the national encouragement list, it is very likely that they will eventually be included in the medical insurance catalog.

At present, China's medical system is not very comprehensive, and there are many diseases that are still not covered by medical insurance, and the scope of medical insurance will be improved and expanded one after another.

Up to now, 2,860 drugs have been included in the national medical insurance catalog, and 67% of the drugs for rare diseases on the market in China are among them, which greatly reduces the drug burden of patients. In the past 10 years, the number of people insured by medical insurance in China has increased from 100 million to 100 million. At the same time, China has built the world's largest basic medical security network.

At present, China's basic medical insurance has covered 100 million people, the coverage rate is stable at more than 95%, and the proportion of hospitalization expenses paid within the scope of the basic medical insurance policy for employees and urban and rural residents is stable at about 80% and 70% respectively. The data shows that the main health indicators of Chinese residents are in the forefront of middle- and high-income countries. The proportion of residents' personal health expenditure has decreased from 2012 to 2021, making it more convenient, affordable, efficient and smoother to seek medical treatment.

As previously reported, "rare diseases" are not uncommon. According to the official website of the American Organization for Rare Diseases (NORD), there are currently more than 7,000 known rare diseases in the world, 80% of which are genetic diseases. While the number of patients with each disease is not large, the number of people affected by thousands of rare diseases is enormous.

According to Nord's official website, there are more than 300 million rare disease patients worldwide, 50% of whom are children. According to the 2021 China Rare Disease Definition Research Report, there are about 20 million rare disease patients in China.

About 80% of rare diseases are caused by genetic factors, and some rare diseases can be diagnosed by genetic testing**, and clinicians with the diagnostic technology and ability of such rare diseases are concentrated in the tertiary hospitals in some provincial capitals of Beijing, Shanghai, Guangzhou, Shenzhen and Shichan.

Clinicians in third- and fourth-tier cities are very difficult to independently diagnose rare diseases due to their lack of professional knowledge related to rare diseases, lack of clinical experience, and limited technical facilities.

China is the only country in the world that delineates rare diseases according to the management of batch disease catalogs. Based on the 121 rare diseases in the "Catalogue of Rare Diseases for Type 1 Returned Batches", 86 rare diseases have the best drugs in the world, of which 77 rare diseases have the best drugs in China, and 9 rare diseases are facing the dilemma of "there are drugs outside the country and no drugs in China". In China, there are 87 drugs with clear indications for rare diseases, involving 43 rare diseases, of which 58 drugs have been included in the national medical insurance as of 2021, covering 29 rare diseases.